Endocrinol Metab.  2024 Dec;39(6):856-863. 10.3803/EnM.2024.2006.

Association of the Preoperative Controlling Nutritional Status (CONUT) Score with Clinicopathological Characteristics in Patients with Papillary Thyroid Carcinoma

• Kim D
• Im M
• Ryang S
• Kim M
• Jeon YK
• Kim SS
• Kim BH

• KMID: 2562714
• DOI: http://doi.org/10.3803/EnM.2024.2006

Abstract

Background
The Controlling Nutritional Status (CONUT) score is an immunonutritional test tool based on serum albumin, total cholesterol, and lymphocyte counts. It has been studied as a simple prognostic predictor for various carcinomas. This study aimed to investigate the association between preoperative CONUT scores and the clinicopathological characteristics in papillary thyroid carcinoma (PTC) patients.
Methods
This study included 2,403 PTC patients who underwent total thyroidectomy between 2012 and 2016 at a single tertiary medical center. The CONUT scores were calculated based on preoperative blood tests. The clinicopathological characteristics were retrospectively reviewed. The patients were categorized by the CONUT score (relatively low, 0–2; relatively high, 3–5).
Results
Among the 2,997 PTC patients who underwent total thyroidectomy at Pusan National University Hospital between 2012 and 2016, those without preoperative blood test were excluded (n=149). Finally 2,403 patients were analyzed after excluding 439 patients taking lipid-lowering drugs and six patients without available T stage data after surgery. Based on the CONUT score, the relatively high score group had a lower body mass index (23.7±3.3 kg/m² vs. 21.9±2.9 kg/m², P<0.001), more advanced T stage (T stage 3/4, 5.9% vs. 11.4%, P=0.045), and higher extrathyroidal extension (2.1% vs. 7.6%, P=0.005).
Conclusion
Patients included in this large, single-center study all had a preoperative CONUT score of 0–5, but this study demonstrated that higher preoperative CONUT scores were significantly associated with advanced T stage and extrathyroidal extension. The CONUT score, which can be easily used in clinical practice, is thought to be helpful in predicting the aggressiveness of PTC.

Keyword

CONUT score; Thyroid cancer, papillary; Nutrition assessment; Prognosis

Figure

• 

  Fig. 1. Flow chart of patient selection. WBC, white blood cell; CONUT, Controlling Nutritional Status.

• 

Reference

1. Bonnefond S, Davies TF. Thyroid cancer: risks and causes. Oncol Hematol Rev. 2014; 10:144–51.

2. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013; 2013:965212.

3. Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130(S2):S150–60.

4. Li W, Li M, Wang T, Ma G, Deng Y, Pu D, et al. Controlling Nutritional Status (CONUT) score is a prognostic factor in patients with resected breast cancer. Sci Rep. 2020; 10:6633.

5. Daitoku N, Miyamoto Y, Tokunaga R, Sakamoto Y, Hiyoshi Y, Iwatsuki M, et al. Controlling Nutritional Status (CONUT) score is a prognostic marker in metastatic colorectal cancer patients receiving first-line chemotherapy. Anticancer Res. 2018; 38:4883–8.

6. Zhang Y, Kong FF, Zhu ZQ, Shan HX. Controlling Nutritional Status (CONUT) score is a prognostic marker in IIIIV NSCLC patients receiving first-line chemotherapy. BMC Cancer. 2023; 23:225.

7. Sun K, Chen S, Xu J, Li G, He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014; 140:1537–49.

8. Fruchtenicht AV, Poziomyck AK, Kabke GB, Loss SH, Antoniazzi JL, Steemburgo T, et al. Nutritional risk assessment in critically ill cancer patients: systematic review. Rev Bras Ter Intensiva. 2015; 27:274–83.

9. Kushiyama S, Sakurai K, Kubo N, Tamamori Y, Nishii T, Tachimori A, et al. The preoperative geriatric nutritional risk index predicts postoperative complications in elderly patients with gastric cancer undergoing gastrectomy. In Vivo. 2018; 32:1667–72.

10. Zheng Z, Zhu H, Cai H. Preoperative prognostic nutritional index predict survival in patients with resectable esophageal squamous cell carcinoma. Front Nutr. 2022; 9:824839.

11. Ignacio de Ulibarri J, Gonzalez-Madrono A, de Villar NG, Gonzalez P, Gonzalez B, Mancha A, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. 2005; 20:38–45.

12. Hirahara N, Tajima Y, Fujii Y, Kaji S, Kawabata Y, Hyakudomi R, et al. Controlling Nutritional Status (CONUT) as a prognostic immunonutritional biomarker for gastric cancer after curative gastrectomy: a propensity score-matched analysis. Surg Endosc. 2019; 33:4143–52.

13. Zhang W, Wu Y, Zhang Z, Guo Y, Wang R, Wang L, et al. Controlling Nutritional Status score: a new prognostic indicator for patients with oligometastatic prostate cancer. Curr Probl Cancer. 2019; 43:461–70.

14. Zhu M, Chen L, Kong X, Wang X, Ren Y, Liu Q, et al. Controlling Nutritional Status (CONUT) as a novel postoperative prognostic marker in breast cancer patients: a retrospective study. Biomed Res Int. 2022; 2022:3254581.

15. Qian Y, Liu H, Pan J, Yu W, Lv J, Yan J, et al. Preoperative Controlling Nutritional Status (CONUT) score predicts shortterm outcomes of patients with gastric cancer after laparoscopy-assisted radical gastrectomy. World J Surg Oncol. 2021; 19:25.

16. Kheirouri S, Alizadeh M. Prognostic potential of the preoperative Controlling Nutritional Status (CONUT) score in predicting survival of patients with cancer: a systematic review. Adv Nutr. 2021; 12:234–50.

17. Huang ZZ, Song CG, Huang JJ, Xia W, Bi XW, Hua X, et al. Prognostic significance of the Controlling Nutritional Status (CONUT) score in surgically treated breast cancer patients. Gland Surg. 2020; 9:1370–9.

18. Chen L, Sun H, Zhao R, Huang R, Pan H, Zuo Y, et al. Controlling Nutritional Status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes. Front Pharmacol. 2022; 13:836958.

19. Wu N, Chen G, Hu H, Pang L, Chen Z. Low pretherapeutic serum albumin as a risk factor for poor outcome in esophageal squamous cell carcinomas. Nutr Cancer. 2015; 67:481–5.

20. Zhou P, Li B, Liu B, Chen T, Xiao J. Prognostic role of serum total cholesterol and high-density lipoprotein cholesterol in cancer survivors: a systematic review and meta-analysis. Clin Chim Acta. 2018; 477:94–104.

21. Gao R, Liang JH, Wang L, Zhu HY, Wu W, Cao L, et al. Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma. Int J Cancer. 2018; 143:1884–95.

22. Tang J, Yin H, Wu JZ, Xia Y, Liang JH, Chen RZ, et al. Low serum cholesterol levels predict inferior prognosis and improve prognostic index scoring for peripheral T-cell lymphoma, unspecified. Leuk Res. 2021; 103:106534.

23. Li B, Huang D, Zheng H, Cai Q, Guo Z, Wang S. Preoperative serum total cholesterol is a predictor of prognosis in patients with renal cell carcinoma: a meta- analysis of observational studies. Int Braz J Urol. 2020; 46:158–68.

24. Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004; 28:e26–31.

25. Degrate L, Nobili C, Franciosi C, Caprotti R, Brivio F, Romano F, et al. Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. Langenbecks Arch Surg. 2009; 394:115–21.

26. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide thyroid-cancer epidemic?: the increasing impact of overdiagnosis. N Engl J Med. 2016; 375:614–7.